Abstract
In 1930, Sir Foster Moore first used brachytherapy for uveal melanoma by inserting radon-222 seeds directly into the tumor (Moore, Br J Ophthalmol 14:145–152, 1930). This technique was later modified by Stallard and eventually further refined using radioactive plaques containing cobalt-60 anchored to the episcleral surface (Stallard, Br J Ophthalmol 32(9):618–639, 1948; Stallard, Br J Ophthalmol 50(3):147–155, 1966). In the United States, this radionuclide was gradually replaced by plaques loaded with iodine-125 seeds, as this provided less radiation to surrounding tissues (Sealy et al., Br J Radiol 49(582):551–554, 1976; Packer and Rotman, Ophthalmology 87(6):582–590, 1980). In Europe, the pioneering work of Lommatzsch in the 1970s led to the introduction of ruthenium-106 as a radioactive source for episcleral brachytherapy of uveal melanoma (Lommatzsch, Surv Ophthalmol 19(2):85–100, 1974). Although observational data suggested that there was no survival difference compared to patients enucleated for uveal melanoma, it had not been confirmed in a randomized control trial until the Collaborative Ocular Melanoma Study (COMS) was launched in the mid-1980s. This included patients with medium-sized uveal melanoma, who had equal 5-year and 10-year survival rates in the enucleation and iodine brachytherapy groups (Collaborative Ocular Melanoma Study Group, Arch Ophthalmol 119:969–982, 2001; Collaborative Ocular Melanoma Study Group, Arch Ophthalmol 124:1684–1693, 2006). Ever since, brachytherapy has been a mainstay treatment within this size group. Smaller tumors are generally observed for growth or in selected cases treated with transpupillary thermotherapy, while patients with larger tumors still undergo enucleation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Moore RF. Choroidal sarcoma treated by the intraocular insertion of radon seeds. Br J Ophthalmol. 1930;14(4):145–52.
Stallard HB. Radiotherapy of malignant intra-ocular neoplasms. Br J Ophthalmol. 1948;32(9):618–39.
Stallard HB. Radiotherapy for malignant melanoma of the choroid. Br J Ophthalmol. 1966;50(3):147–55.
Sealy R, le Roux PL, Rapley F, et al. The treatment of ophthalmic tumours with low-energy sources. Br J Radiol. 1976;49(582):551–4.
Packer S, Rotman M. Radiotherapy of choroidal melanoma with iodine-125. Ophthalmology. 1980;87(6):582–90.
Lommatzsch P. Treatment of choroidal melanomas with 106Ru/106Rh beta-ray applicators. Surv Ophthalmol. 1974;19(2):85–100.
Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. III. Initial mortality findings. COMS report No. 18. Arch Ophthalmol. 2001;119:969–82.
Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. V. Twelve-year mortality rates and prognostic factors. COMS report No. 28. Arch Ophthalmol. 2006;124:1684–93.
Stannard C, Sauerwein W, Maree G, et al. Radiotherapy for ocular tumours. Eye (Lond). 2013;27(2):119–27.
Bergman L, Nilsson B, Lundell G, et al. Ruthenium brachytherapy for uveal melanoma, 1979–2003: survival and functional outcomes in the Swedish population. Ophthalmology. 2005;112(5):834–40.
Damato B, Patel I, Campbell IR, et al. Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys. 2005;63(2):385–91.
Finger PT, Chin KJ, Duvall G, et al. Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients. Ophthalmology. 2009;116(4):790–6. 796.e1.
Karvat A, Duzenli C, Ma R, et al. The treatment of choroidal melanoma with 198 Au plaque brachytherapy. Radiother Oncol. 2001;59(2):153–6.
Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol. 2000;118(9):1219–28.
Missotten L, Dirven W, Van der Schueren A, et al. Results of treatment of choroidal malignant melanoma with high-dose-rate strontium-90 brachytherapy. A retrospective study of 46 patients treated between 1983 and 1995. Graefes Arch ClinExpOphthalmol. 1998;236(3):164–73.
The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13(1):1–14.
Echegaray JJ, Bechrakis NE, Singh N, et al. Iodine-125 brachytherapy for uveal melanoma: a systematic review of radiation dose. Ocul Oncol Pathol. 2017;3(3):193–8.
Fili M, Lundell G, Lundell M, et al. High dose rate and low dose rate ruthenium brachytherapy for uveal melanoma. No association with ocular outcome. Br J Ophthalmol. 2014;98(10):1349–54.
Shah NV, Houston SK, Murray TG, et al. Evaluation of the surgical learning curve for I-125 episcleral plaque placement for the treatment of posterior uveal melanoma: a two decade review. Clin Ophthalmol. 2012;6:447–52.
Gunduz K, Shields CL, Shields JA, et al. Plaque radiotherapy for management of ciliary body and choroidal melanoma with extraocular extension. Am J Ophthalmol. 2000;130(1):97–102.
Muen WJ, Damato BE. Uveal malignant melanoma with extrascleral extension, treated with plaque radiotherapy. Eye (Lond). 2007;21(2):307–8.
Williams DF, Mieler WF, Jaffe GJ, et al. Magnetic resonance imaging of juxtapapillary plaques in cadaver eyes. Br J Ophthalmol. 1990;74(1):43–6.
Damato B, Patel I, Campbell IR, et al. Visual acuity after Ruthenium(106) brachytherapy of choroidal melanomas. Int J Radiat Oncol Biol Phys. 2005;63(2):392–400.
Tabandeh H, Chaudhry NA, Murray TG, et al. Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma. Am J Ophthalmol. 2000;129(2):199–204.
Russo A, Laguardia M, Damato B. Eccentric ruthenium plaque radiotherapy of posterior choroidal melanoma. Graefes Arch Clin Exp Ophthalmol. 2012;250:1533–40.
Augsburger JJ, Gamel JW, Shields JA, et al. Post-irradiation regression of choroidal melanomas as a risk factor for death from metastatic disease. Ophthalmology. 1987;94(9):1173–7.
Rashid M, Heikkonen J, Singh AD, et al. Clinical predictors of regression of choroidal melanomas after brachytherapy: a growth curve model. Ophthalmology. 2018;125(5):747–54.
Damato B. Predicting choroidal melanoma regression after brachytherapy. Ophthalmology. 2018;125(5):755–6.
Laube T, Fluhs D, Kessler C, et al. Determination of surgeon’s absorbed dose in iodine 125 and ruthenium 106 ophthalmic plaque surgery. Ophthalmology. 2000;107(2):366–8; discussion 368–9.
Shields CL, Naseripour M, Shields JA, et al. Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications. Am J Ophthalmol. 2003;135(5):648–56.
Fluhs D, Anastassiou G, Wening J, et al. The design and the dosimetry of bi-nuclide radioactive ophthalmic applicators. Med Phys. 2004;31(6):1481–8.
Astrahan MA, Szechter A, Finger PT. Design and dosimetric considerations of a modified COMS plaque: the reusable “seed-guide” insert. Med Phys. 2005;32(8):2706–16.
Seregard S, Landau I. Transpupillary thermotherapy as an adjunct to ruthenium plaque radiotherapy for choroidal melanoma. Acta Ophthalmol Scand. 2001;79(1):19–22.
Bartlema YM, Oosterhuis JA, Journee-De Korver JG, et al. Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years’ experience. Br J Ophthalmol. 2003;87(11):1370–3.
Damato BE, Paul J, Foulds WS. Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection. Br J Ophthalmol. 1996;80(2):102–8.
Damato BE, Groenewald C, Foulds WS. Surgical resection of choroidal melanoma. In: Ryan SJ, editor. Retina, vol. 3. 5th ed. London: Elsevier; 2013. p. 2298–306.
Puusaari I, Heikkonen J, Kivela T. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques. Invest Ophthalmol Vis Sci. 2004;45(10):3425–34.
Collaborative Ocular Melanoma Study. Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine 125 brachytherapy in the Collaborative Ocular Melanoma Study: COMS report No. 27. Ophthalmology. 2007;114(7):1363–71.
Wen JC, Oliver SC, McCannel TA. Ocular complications following I-125 brachytherapy for choroidal melanoma. Eye (Lond). 2009;23(6):1254–68.
Robertson DM, Fuller DG, Anderson RE. A technique for accurate placement of episcleral iodine-125 plaques. Am J Ophthalmol. 1987;103(1):63–5.
Finger PT. Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol. 2000;84(9):1068–70.
Summanen P, Immonen I, Kivela T, et al. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma. Br J Ophthalmol. 1996;80(8):732–9.
Krema H, Xu W, Payne D, et al. Factors predictive of radiation retinopathy post (125)Iodine brachytherapy for uveal melanoma. Can J Ophthalmol. 2011;46(2):158–63.
Mourtada F, Koch N, Newhauser W. 106Ru/106Rh plaque and proton radiotherapy for ocular melanoma: a comparative dosimetric study. Radiat Prot Dosimetry. 2005;116(1–4 Pt 2):454–60.
Finger PT, Kurli M. Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol. 2005;89(6):730–8.
Damato B. Vasculopathy after treatment of choroidal melanoma. In: Joussen A, Gardner TW, Kirchhof B, Ryan SJ, editors. Retinal vascular disease. Berlin: Springer; 2007. p. 582–91.
Shields CL, Demirci H, Dai V, et al. Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma. Retina. 2005;25(7):868–74.
Horgan N, Shields CL, Mashayekhi A, et al. Periocular triamcinolone for prevention of macular edema after plaque radiotherapy of uveal melanoma: a randomized controlled trial. Ophthalmology. 2009;116(7):1383–90.
Shah SU, Shields CL, Bianciotto CG, et al. Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma. Ophthalmology. 2014;121(1):269–75.
Khan N, Khan MK, Bena J, et al. Plaque brachytherapy for uveal melanoma: a vision prognostication model. Int J Radiat Oncol Biol Phys. 2012;84(3):e285–90.
Groenewald C, Konstantinidis L, Damato B. Effects of radiotherapy on uveal melanomas and adjacent tissues. Eye (Lond). 2013;27(2):163–71.
Finger PT. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys. 2008;70(4):974–7.
Detorakis ET, Engstrom RE Jr, Wallace R, et al. Iris and anterior chamber angle neovascularization after iodine 125 brachytherapy for uveal melanoma. Ophthalmology. 2005;112(3):505–10.
Kaliki S, Shields CL, Rojanaporn D, et al. Scleral necrosis after plaque radiotherapy of uveal melanoma: a case–control study. Ophthalmology. 2013;120:1004–11.
Melia BM, Abramson DH, Albert DM, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001;108(2):348–66.
Puusaari I, Heikkonen J, Summanen P, et al. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmology. 2003;110(11):2223–34.
Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology. 2002;109(12):2197–206.
Sagoo MS, Shields CL, Mashayekhi A, et al. Plaque radiotherapy for juxtapapillarychoroidal melanoma: tumor control in 650 consecutive cases. Ophthalmology. 2011;118(2):402–7.
Papageorgiou KI, Cohen VM, Bunce C, et al. Predicting local control of choroidal melanomas following 106Ru plaque brachytherapy. Br J Ophthalmol. 2011;95(2):166–70.
Filì M, Trocmé E, Bergman L, et al. Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm. Br J Ophthalmol. 2019; https://doi.org/10.1136/bjophthalmol-2018-313419. [Epub ahead of print]
Seregard S, Lundell G, Lax I, et al. Tumour cell proliferation after failed ruthenium plaque radiotherapy for posterior uveal melanoma. Acta Ophthalmol Scand. 1997;75(2):148–54.
Avery RB, Diener-West M, Reynolds SM, et al. Histopathologic characteristics of choroidal melanoma in eyes enucleated after iodine 125 brachytherapy in the collaborative ocular melanoma study. Arch Ophthalmol. 2008;126(2):207–12.
Toivonen P, Kivela T. Pigmented episcleral deposits after brachytherapy of uveal melanoma. Ophthalmology. 2006;113(5):865–73.
Seregard S, aft Trampe E, Lax I, et al. Results following episcleral ruthenium plaque radiotherapy for posterior uveal melanoma. The Swedish experience. Acta Ophthalmol Scand. 1997;75(1):11–6.
Arnljots TS, Al-Sharbaty Z, Lardner E, et al. Tumour thickness, diameter, area or volume? The prognostic significance of conventional versus digital image analysis-based size estimation methods in uveal melanoma. Acta Ophthalmol Scand. 2018;96(5):510–8.
Brandberg Y, Kock E, Oskar K, et al. Psychological reactions and quality of life in patients with posterior uveal melanoma treated with ruthenium plaque therapy or enucleation: a one year follow-up study. Eye (Lond). 2000;14(Pt 6):839–46.
Brandberg Y, Damato B, Kivela T, et al. The EORTC ophthalmic oncology quality of life questionnaire module (EORTC QLQ-OPT30). Development and pre-testing (Phase I-III). Eye (Lond). 2004;18(3):283–9.
Damato B, Hope-Stone L, Cooper B, et al. Patient-reported outcomes and quality of life after treatment of choroidal melanoma. A comparison of enucleation versus radiotherapy in 1596 patients. Am J Ophthalmol. 2018;193(1):230–51.
Shields CL, Naseripour M, Cater J, et al. Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients. Ophthalmology. 2002;109(10):1838–49.
Stålhammar G, See TRO, Filì M, et al. No gender differences in long-term survival after brachytherapy of 1,541 patients with uveal melanoma. Ocul Oncol Pathol. 2019; https://doi.org/10.1159/000497186. [Epub ahead of print].
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Stålhammar, G., Seregard, S., Damato, B.E. (2019). Uveal Melanoma: Brachytherapy. In: Damato, B., Singh, A. (eds) Clinical Ophthalmic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-17879-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-030-17879-6_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-17878-9
Online ISBN: 978-3-030-17879-6
eBook Packages: MedicineMedicine (R0)